Literature DB >> 14990210

Management issues for elderly patients with breast cancer.

Martine Extermann1.   

Abstract

Fifty percent of breast cancers occur after the age of 65 years and 25% occur after the age of 75 years. Encountering a breast cancer in an older woman is frequent. After years of dearth of data specific to the elderly, some evidence is beginning to accumulate concerning breast cancer in the older woman. Recent data from mammography studies confirm its effective in women with 10 years or more of life expectancy (perhaps even 5 years). Epidemiologic and randomized studies demonstrate that a proper surgery and adjuvant treatment can decrease relapse and improve survival in patients older than 80 years. Radiation therapy studies show a decrease in local relapse even in patients older than 70 years. Adjuvant hormonal therapy has essentially the same effectiveness as in younger women. Chemotherapy has a role in patients older than 70 years. Consensus statements, such as the St. Gallen consensus, have dropped the age limit of 70 years from their recommendations. Comorbidity and life expectancy should be taken into account for proper selection of adjuvant treatment. The treatment of metastatic breast cancer has evolved significantly with the introduction of aromatase inhibitors, new chemotherapeutic agents, and targeted biologic agents. New chemotherapeutic agents are as effective as single agents compared to older and more toxic drug combinations. The cumulative result of the introduction of these new agents, at a population level, is a 7.5-month increase in the median survival time of patients with metastatic breast cancer over the past decade.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990210     DOI: 10.1007/s11864-004-0048-9

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  49 in total

Review 1.  Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

Authors:  D Schrijvers; M Highley; E De Bruyn; A T Van Oosterom; J B Vermorken
Journal:  Anticancer Drugs       Date:  1999-02       Impact factor: 2.248

2.  Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin.

Authors:  A Venturino; D Comandini; C Simoni; L Merlini; C Naso; R Palumbo; V Fusco; G Porcile; P Pronzato; R Rosso; L Repetto
Journal:  Breast Cancer Res Treat       Date:  2000-04       Impact factor: 4.872

3.  Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.

Authors:  J Bonneterre; A Buzdar; J M Nabholtz; J F Robertson; B Thürlimann; M von Euler; T Sahmoud; A Webster; M Steinberg
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

Review 4.  National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.

Authors: 
Journal:  J Natl Cancer Inst Monogr       Date:  2001

5.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Authors:  J Cuzick; J Forbes; R Edwards; M Baum; S Cawthorn; A Coates; A Hamed; A Howell; T Powles
Journal:  Lancet       Date:  2002-09-14       Impact factor: 79.321

6.  Representation of older patients in cancer treatment trials.

Authors:  E L Trimble; C L Carter; D Cain; B Freidlin; R S Ungerleider; M A Friedman
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

7.  The effect of tumor size and lymph node status on breast carcinoma lethality.

Authors:  James S Michaelson; Melvin Silverstein; Dennis Sgroi; Justin A Cheongsiatmoy; Alphonse Taghian; Simon Powell; Kevin Hughes; Arthur Comegno; Kenneth K Tanabe; Barbara Smith
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

8.  The effects of mammographic detection and comorbidity on the survival of older women with breast cancer.

Authors:  Carol P McPherson; Karen K Swenson; Martin W Lee
Journal:  J Am Geriatr Soc       Date:  2002-06       Impact factor: 5.562

9.  Barriers to clinical trial participation by older women with breast cancer.

Authors:  M Margaret Kemeny; Bercedis L Peterson; Alice B Kornblith; Hyman B Muss; Judith Wheeler; Ellis Levine; Nancy Bartlett; Gini Fleming; Harvey J Cohen
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

10.  Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.

Authors:  J Bonneterre; H Roché; A Monnier; J P Guastalla; M Namer; P Fargeot; S Assadourian
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

View more
  7 in total

1.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

2.  Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.

Authors:  Yo Han Cho; Sung Yong Kim; M Hong Lee; Moon-Won Yoo; Ho-Yoon Bang; Kyung-Yung Lee; So Young Yoon
Journal:  Gastric Cancer       Date:  2012-01-12       Impact factor: 7.370

3.  Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up.

Authors:  Kerri M Clough-Gorr; Andreas E Stuck; Soe Soe Thwin; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

4.  Multiple primary malignancies in elderly patients with high-grade soft tissue sarcoma.

Authors:  Eiji Kozawa; Hideshi Sugiura; Satoshi Tsukushi; Hiroshi Urakawa; Eisuke Arai; Naohisa Futamura; Hiroatsu Nakashima; Yoshihisa Yamada; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Int J Clin Oncol       Date:  2013-03-20       Impact factor: 3.402

5.  Optimising surgical management of elderly cancer patients.

Authors:  Hodigere Sripathy Jois Ramesh; Daniel Pope; Roberto Gennari; Riccardo A Audisio
Journal:  World J Surg Oncol       Date:  2005-03-23       Impact factor: 2.754

6.  Prediction of Female Breast Cancer Incidence among the Aging Society in Kanagawa, Japan.

Authors:  Kayoko Katayama; Hiroto Narimatsu
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

7.  Conservative management of breast cancer in the elderly in a developing country.

Authors:  Lukas J Wasserman; Justus P Apffelstaedt; Jacobus de V Odendaal
Journal:  World J Surg Oncol       Date:  2007-10-01       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.